Last reviewed · How we verify

The Use of Polyclonal Anti-T-Lymphocyte Globulin to Prevent Progression of Autoimmune Beta-Cell Destruction in Recent Type 1 Diabetes

NCT00190502 NA UNKNOWN

The primary objective of the study is: * To compare the effect of ATG treatment together with intensified insulin therapy (Group 1) on fasting and glucagon-stimulated C-peptide production with that of intensified insulin therapy only (Group 2) in type 1 diabetes mellitus of recent onset Secondary objectives are: * To compare the insulin doses between the two groups at 6, 12, 18, and 24 months after diabetes onset * To compare the course of the specific humoral markers of autoimmunity between the groups * To evaluate the significance of in vitro testing of specific T-cell activation by an autoantigen in the long-term follow-up in type 1 diabetes * To assess the safety of ATG treatment in type 1 diabetes

Details

Lead sponsorInstitute for Clinical and Experimental Medicine
PhaseNA
StatusUNKNOWN
Enrolment28
Start date2000-11
Completion2007-12

Conditions

Interventions

Primary outcomes

Countries

Czechia